Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Avid Bioservices, Inc. | Contract Pharma

What are you searching for?

Sign in

Search by

Avid Bioservices, Inc.

Company Headquarters

14191 Myford Road , Orange County, Tustin, CA, 92780, US

Driving Directions Phone: View Phone
View website

Request more information from Avid Bioservices, Inc.

Request more information from Avid Bioservices, Inc.

Categories from Avid Bioservices, Inc.

Accelerated Stability Studies
Analytical Methods Development
Analytical Validation Studies
Assay Development
Bioanalytical Analysis LC/MS/MS
Biological Testing
Biologics Manufacturing
Biologics Process Development
Bioprocess Validation
Bioprocessing
Bioprocessing, Disposable/Single-Use
Biosimilars
Chromatographic Analysis, LC/GC
Clean in Place / Sterilization in Place (CIP/SIP)
CMC (Chemistry, Manfacturing & Controls)
Contract Development and Manufacturing Organization (CDMO)
Contract Manufacturing
Custom Manufacturing
Downstream Processing
Drug Development Services
Feasibility Studies
Forced Degradation Studies
Gene Therapy & Testing Protocols
High Throughput Screening
HPLC
Lot Release Testing
Mammalian Cell Culture
Manufacturing, Antibody-Drug Conjugates
Manufacturing, API
Manufacturing, Biologics
Manufacturing, Clinical Trials Supply
Manufacturing, Custom
Manufacturing, Proteins
Manufacturing, Vaccines
Methods Development
Methods Validation
Process Characterization
Process Development/Scale-Up Services
Process R&D
Process Validation Studies
Project Management
Protein Extraction/Purification
Purification
QA/QC
Quality Control Testing
R&D Services
Scale-Up
Stability Studies
Stability, ICH
Technology Transfer
Validation, Manufacturing
Validation, Services
Making the Switch to Single-Use Technologies

Sponsored Content

Making the Switch to Single-Use Technologies

Why Avid Bioservices adopted single-use technologies over thirteen years ago and never looked back.

Released By Avid Bioservices, Inc.

Related Content

Breaking News

Avid Bioservices Opens Early Phase Center of Excellence in CA

Expands Avid's development footprint and strengthens its ability to provide end-to-end services from cell line development through commercial manufacturing.

By: Charlie Sternberg

Promotions & Moves

Avid Bioservices Taps Rich McAvoy as Chief Business Officer

McAvoy offers experience spanning strategic investment management, operational finance, accounting, legal, compliance, and risk management.

By: Charlie Sternberg

Promotions & Moves

Avid Bioservices Appoints Kenneth Bilenberg as CEO

Bilenberg is a seasoned industry executive with more than 20 years of experience.

By: Charlie Sternberg

Breaking News

Sanner Rebrands Gilero, Expands Chicago Facility

North American expansion strengthens CDMO support for medtech and healthcare packaging.

By: Charlie Sternberg

Collaborations & Alliances

Bespak and Upperton Partner on Nasal Drug Delivery

The CDMO collaboration will combine Bespak’s nasal device portfolio with Upperton’s formulation, analytical and clinical manufacturing expertise.

By: Charlie Sternberg

Breaking News

Kincell Bio, Cellipont Merge to Form Kincellis Advanced Therapies

New advanced therapies CDMO combines immune-cell, stem-cell and mRNA-enabled capabilities across three U.S. sites.

By: Charlie Sternberg

Online Exclusives

CDMO Capacity: Stainless by Volume, Single-Use by Number

Large stainless-steel projects are rising, but pipeline demand is increasingly moving toward smaller, more flexible manufacturing models.

By: Dan Stanton

Sponsored Videos

Cohance Lifesciences: A Global CDMO Platform with Multi-Modality Expertise

Small Molecules. ADCs. Nucleic Acid Chemistry.

Released By Cohance Lifesciences

Breaking News

Fareva Expands CDMO Network With Türkiye Site

The Lüleburgaz facility adds major production capacity, technical expertise, and international client reach.

By: Charlie Sternberg

Promotions & Moves

Symbiosis Names Jos Vergeest Senior Business Development Director

Former GSK, AstraZeneca and CDMO executive joins to support international growth.

By: Charlie Sternberg

Breaking News

CordenPharma Expands Injectable Manufacturing in Italy

The CDMO is adding new property, aseptic fill-finish lines, packaging capacity, and analytical capabilities at its Caponago site near Milan.

By: Charlie Sternberg

Features

Inside the Changing HPAPI Manufacturing Landscape

Highly potent compounds are reshaping CDMO expectations, from early risk assessment to closed, automated containment facilities.

By: Charlie Sternberg

Northway Biotech Opens €61M Cell Therapy CDMO Facility in Vilnius

The 3,500-square-meter BIO CITY III facility adds up to 20 cGMP manufacturing lines for cell therapies and personalized medicine.

By: Tim Wright

Sponsored Content

Benchmark Study: Trends and Challenges in Bioconjugate Developement & Manufacturing

New benchmark study explores trends and challenges in bioconjugate and ADC development, from linker-payload chemistry to CDMO selection criteria.

Released By Lonza

Promotions & Moves

Symbiosis Appoints Jay Chima as VP, Business Development

Chima brings more than 16 years of commercial experience across pharma, biotech and CDMO markets.

By: Charlie Sternberg

Pharma Matters Q&A

From Phase 3 to Commercialization: What Sponsors Need from a Sterile Injectable CDMO

August Bioservices’ Ryan Downey discusses fill-finish capacity, Annex 1 readiness, technical expertise and the infrastructure needed to move injectable programs toward commercial launch.

Released By August Bioservices

Collaborations & Alliances

Andelyn Biosciences Partners With Queen’s University on GM2 Gene Therapy

CDMO to manufacture AAV9-GM2 candidate for Tay-Sachs and Sandhoff diseases.

By: Charlie Sternberg

Pharma Matters Q&A

Engineering a Flawless Scale-Up: How CDMOs De-Risk the Path to Commercial Supply

Aligning manufacturing capacity with long-term client goals ensures products transition smoothly with consistent performance.

Released By Grand River Aseptic Manufacturing